Obesity (Silver Spring, Md.)最新文献

Effects of Time-Restricted Eating on Gut Microbiota and Metabolites and Their Relationship With Cardiometabolic Risk Factors. 限时进食对肠道菌群和代谢物的影响及其与心脏代谢危险因素的关系

Obesity (Silver Spring, Md.) Pub Date : 2026-05-08 DOI: 10.1002/oby.70207

Li-Min Zhang, Zi-Dan Wang, Zheng Zhang, Jie Liu, Zhi-Hao Li, Yue-Rong Ren, Zhan Liu, Xiao Zhang, Xian-Yun Wang, Ke-Xin Qi, Chang Yuan, Hao Guo, Yi-Fei Zhang, Jun Ge, Yu-Xia Ma

{"title":"Effects of Time-Restricted Eating on Gut Microbiota and Metabolites and Their Relationship With Cardiometabolic Risk Factors.","authors":"Li-Min Zhang, Zi-Dan Wang, Zheng Zhang, Jie Liu, Zhi-Hao Li, Yue-Rong Ren, Zhan Liu, Xiao Zhang, Xian-Yun Wang, Ke-Xin Qi, Chang Yuan, Hao Guo, Yi-Fei Zhang, Jun Ge, Yu-Xia Ma","doi":"10.1002/oby.70207","DOIUrl":"https://doi.org/10.1002/oby.70207","url":null,"abstract":"Objective: This study aimed to investigate whether the time of the eating window during time-restricted eating (TRE) alters the gut microbiota and metabolomic profiles and to determine their relationship with cardiometabolic risk factors in adults with overweight or obesity.Methods: In an 8-week randomized controlled trial, 60 young adults with overweight or obesity were randomized to 6-h eTRE (7 a.m.-1 p.m.), 6-h lTRE (12 p.m.-6 p.m.), or a control group (ad libitum). The gut microbiota was analyzed by 16S ribosomal RNA (16S rRNA) sequencing and serum metabolomics were quantified by liquid chromatography-mass spectrometry (LC-MS).Results: After 8 weeks, compared to the control group, the 6-h eTRE increased abundance of Faecalibacterium and Lactobacillus and decreased abundance of unclassified_f_Peptostreptococcaceae, whereas 6-h lTRE significantly increased abundance of Faecalibacterium and decreased abundance of Shigella (all p < 0.05). Differential serum metabolites (e.g., L-malic acid in eTRE; isovaleric acid in lTRE) were significantly associated with changes in weight, body fat, and systolic blood pressure (SBP) (p < 0.05).Conclusions: Time-restricted eating may be beneficial to weight loss and cardiometabolic health improvement by regulating gut microbiota and serum metabolites.Trial registration: Chinese Clinical Trial Registry ChiCTR2000039115.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity. 西马鲁肽与减肥手术：比较糖尿病和肥胖患者的成本和临床结果。

Obesity (Silver Spring, Md.) Pub Date : 2026-05-06 DOI: 10.1002/oby.70209

Karan R Chhabra, Nihan Gencerliler, Babak J Orandi, Vivian Hsing-Chun Wang, Akio Kozato, Aditya Surapaneni, Morgan Grams, Amrita Mukhopadhyay, Jung-Im Shin, Christine Ren-Fielding, Manish Parikh, Donglan S Zhang

{"title":"Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity.","authors":"Karan R Chhabra, Nihan Gencerliler, Babak J Orandi, Vivian Hsing-Chun Wang, Akio Kozato, Aditya Surapaneni, Morgan Grams, Amrita Mukhopadhyay, Jung-Im Shin, Christine Ren-Fielding, Manish Parikh, Donglan S Zhang","doi":"10.1002/oby.70209","DOIUrl":"https://doi.org/10.1002/oby.70209","url":null,"abstract":"Objective: We compared health care spending and utilization associated with semaglutide relative to bariatric surgery in patients with obesity and type 2 diabetes (T2D).Methods: Using MarketScan insurance claims of patients with BMI ≥ 35 and T2D from 2016 to 2021, we examined associations between choice of semaglutide, sleeve gastrectomy, or gastric bypass; 3-year health care spending (out-of-pocket [OOP] and total); and clinical outcomes (ED visits, hospital admissions, and major adverse cardiovascular events [MACE]). Analyses were adjusted using generalized linear models, inverse probability weighting, and instrumental variables.Results: Among 6748 patients (2797 semaglutide, 2300 sleeve gastrectomy, 1651 gastric bypass), bariatric surgery patients had higher BMI and more comorbidities. In IPTW-adjusted analysis, semaglutide was associated with the highest 3-year OOP costs ($7752 vs. $5980 [sleeve gastrectomy] vs. $6591 [gastric bypass], p < 0.001), but total spending was not statistically different across the groups. Relative to semaglutide, the gastric bypass group showed higher observed ED visits (hazard ratio relative to semaglutide [95% CI]: 1.36 [1.28-1.45]) and inpatient admissions (1.25 [1.13-1.37]) and fewer MACE (0.71 [0.59-0.88]). Sleeve gastrectomy was associated with fewer long-term admissions (0.79 [0.72-0.86]) and MACE (0.79 [0.66-0.93]).Conclusions: For patients with T2D and obesity, compared with semaglutide, bariatric surgery is associated with lower OOP spending and similar total spending at 3 years, as well as lower long-term MACE rates.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disseminating and Implementing the Science of Pediatric Obesity Treatment and Prevention. 传播和实施儿童肥胖治疗和预防科学。

Obesity (Silver Spring, Md.) Pub Date : 2026-05-05 DOI: 10.1002/oby.70197

Amanda E Staiano, Paul A Estabrooks, Gabriela Buccini, Stephen R Cook, Ann M Davis, Kirsten Davison, Lauren Fiechtner, William J Heerman, Jennie L Hill, Thomas H Inge, Elissa Jelalian, Aaron S Kelly, Corby K Martin, Gabriella M McLoughlin, Leanne M Redman, Cara Ruggiero, Justin Ryder, Asheley C Skinner, Brooke Sweeney, Peter T Katzmarzyk

{"title":"Disseminating and Implementing the Science of Pediatric Obesity Treatment and Prevention.","authors":"Amanda E Staiano, Paul A Estabrooks, Gabriela Buccini, Stephen R Cook, Ann M Davis, Kirsten Davison, Lauren Fiechtner, William J Heerman, Jennie L Hill, Thomas H Inge, Elissa Jelalian, Aaron S Kelly, Corby K Martin, Gabriella M McLoughlin, Leanne M Redman, Cara Ruggiero, Justin Ryder, Asheley C Skinner, Brooke Sweeney, Peter T Katzmarzyk","doi":"10.1002/oby.70197","DOIUrl":"https://doi.org/10.1002/oby.70197","url":null,"abstract":"Objective: Pennington Biomedical Research Center convened a scientific symposium in March-April 2025, which brought together leaders in dissemination and implementation science to identify what is known and what is needed to foster the rapid dissemination and implementation of evidence-based, guideline-backed pediatric obesity prevention and treatment interventions.Methods: The primary aim of the symposium was to identify effective dissemination and implementation strategies, contextual factors related to strategy selection, and mechanisms of successful intervention reach, adoption, implementation, and maintenance. Through this symposium, the overarching goal was to accelerate the rate of translation of evidence-based interventions for the prevention and treatment of pediatric obesity into practice while advancing dissemination and implementation science in settings including health care, schools, and the community.Results and conclusions: This article summarizes the state of the scientific evidence discussed at the symposium, identifies exemplars of implementation-effectiveness trials, and provides recommendations for disseminating and implementing evidence-based pediatric obesity prevention and treatment interventions into typical clinical and community settings.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Plasma Free Fatty Acid Carrier Proteome is Altered in Diet-Induced and Genetically Obese Mice. 饮食诱导和遗传性肥胖小鼠血浆游离脂肪酸载体蛋白质组的改变

Obesity (Silver Spring, Md.) Pub Date : 2026-05-05 DOI: 10.1002/oby.70214

Keigo Tomoo, Yi Zhang, Ariana Zoe Diaz Portalatin, Gregory C Henderson

{"title":"The Plasma Free Fatty Acid Carrier Proteome is Altered in Diet-Induced and Genetically Obese Mice.","authors":"Keigo Tomoo, Yi Zhang, Ariana Zoe Diaz Portalatin, Gregory C Henderson","doi":"10.1002/oby.70214","DOIUrl":"https://doi.org/10.1002/oby.70214","url":null,"abstract":"Objective: We aimed to examine the effect of obesity on the plasma free fatty acid (FFA) carrier proteome in mice.Methods: From 6 to 20 weeks of age, male and female C57BL/6J wild-type mice were fed either a low-fat diet (10% of kilocalories from fat) or a high-fat diet (60% of kilocalories from fat), and leptin-deficient ob/ob mice were fed a low-fat diet. Plasma FFA carrier proteins were isolated using a fatty acid pulldown assay and detected by proteomics. Plasma proteins and lipoprotein particles were separated by fast protein liquid chromatography (FPLC). Hepatic gene expression was quantified by qPCR.Results: In each sex, 284 FFA carrier proteins were detected, with dozens of differentially abundant proteins between lean and obese groups. We identified eight proteins that exhibited altered abundance in both models of obesity for both sexes, with the majority transcribed in the liver. Interestingly, proteins with lower or higher abundance in the plasma FFA carrier proteome in obesity showed correspondingly altered gene expression in the liver. Furthermore, FFAs coeluted with lipoprotein particles in FPLC fractions, with accentuated FFA levels in the low-density lipoprotein fractions in obesity.Conclusions: Obesity remodels the spectrum of plasma FFA carriers, potentially via changes in gene expression and lipoprotein abundance.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Disease and Obesity Medications in Older Women by Obesity-Related Cancers Status: SEER-Medicare 2007-2015. 老年妇女心血管疾病和肥胖药物与肥胖相关的癌症状态：SEER-Medicare 2007-2015

Obesity (Silver Spring, Md.) Pub Date : 2026-05-04 DOI: 10.1002/oby.70211

David S Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández-Pérez, Maryam R Hussain, Mohanad Albayyaa, Rasmi Nair, Yong-Fang Kuo, Jaime P Almandoz, Lindsay G Cowell, Sarah E Messiah

{"title":"Cardiovascular Disease and Obesity Medications in Older Women by Obesity-Related Cancers Status: SEER-Medicare 2007-2015.","authors":"David S Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández-Pérez, Maryam R Hussain, Mohanad Albayyaa, Rasmi Nair, Yong-Fang Kuo, Jaime P Almandoz, Lindsay G Cowell, Sarah E Messiah","doi":"10.1002/oby.70211","DOIUrl":"https://doi.org/10.1002/oby.70211","url":null,"abstract":"Objective: This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity-related cancers (ORCa) and age-matched cancer-free populations.Methods: We conducted a retrospective cohort study using SEER-Medicare data from 2007 to 2015. The study included 46,552 women aged ≥ 65 years: ORCa survivors (n = 23,276) and age- and index-matched cancer-free women (n = 23,276). Prediagnostic AOM prescriptions before CVD onset were examined using intent-to-treat (ITT) and per-protocol approaches. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% CI for incident CVD.Results: In ITT analyses, AOM use was associated with lower CVD incidence in the composite analytic sample (HR = 0.80, 95% CI: 0.71-0.90) and among cancer-free women (HR = 0.70, 95% CI: 0.58-0.85). Among ORCa survivors, estimates suggested a similar direction but were not statistically significant. In per-protocol analyses, AOM use was associated with reduced CVD risk in ORCa survivors (HR = 0.74, 95% CI: 0.57-0.94) and cancer-free women (HR = 0.59, 95% CI: 0.45-0.77). These associations were more pronounced within the first 2 years of follow-up.Conclusions: AOM use was inversely associated with incident CVD among ORCa survivors and cancer-free women. Further studies of second-generation AOM, particularly glucagon-like peptide-1 receptor agonists, are warranted.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-Like Peptide-1 Receptor Agonists: Considerations for Treating Preconception Obesity. 胰高血糖素样肽-1受体激动剂：治疗孕前肥胖的考虑。

Obesity (Silver Spring, Md.) Pub Date : 2026-05-04 DOI: 10.1002/oby.70210

Lauren T Berube, Michael A Weintraub, Hedda L Boege, Cheryl R Stein, Andrea L Deierlein

引用次数: 0

One-Year Weight Loss Following a Remote Culinary Medicine Program: A Bi-Center Randomized Controlled Trial. 远程烹饪医学项目后一年体重减轻：一项双中心随机对照试验。

Obesity (Silver Spring, Md.) Pub Date : 2026-05-01 Epub Date: 2026-04-07 DOI: 10.1002/oby.70193

Rani Polak, Maggi A Budd, Adi Finkelstein, Rebecca Goldsmith, Richard Goldstein, Brianna E Gray, Rom Keshet, Amir Tirosh

{"title":"One-Year Weight Loss Following a Remote Culinary Medicine Program: A Bi-Center Randomized Controlled Trial.","authors":"Rani Polak, Maggi A Budd, Adi Finkelstein, Rebecca Goldsmith, Richard Goldstein, Brianna E Gray, Rom Keshet, Amir Tirosh","doi":"10.1002/oby.70193","DOIUrl":"10.1002/oby.70193","url":null,"abstract":"Introduction: Health-related culinary intervention, termed culinary medicine (CM), is an innovative evidence-based strategy in the field of nutrition to improve dietary quality and prevent/manage chronic diseases. Long-term effects on dietary intake and obesity using well-designed studies are limited.Methods: A randomized controlled trial evaluated the impact of a CM intervention on body weight. Participants were age 25-70 with BMI 27.5-35 kg/m2.Intervention: Dietary counseling and twelve 30-min CM sessions.Control: Dietary counseling and CM resources. Body weight, nutrition, and health outcomes were measured at 0, 3, 6, and 12 months.Results: Fifty participants are included in a modified intention to treat analysis. Average intervention group weight loss was: at 3 months, -3.23% (3.52%), net difference -2.52% (CI: -0.48% to -4.56%; p = 0.016); at 6 months, -4.2% (5.24%), net difference -2.98% (CI: -0.36% to -5.60%; p = 0.027); and at 12 months, -4.02% (6.24%), net difference -4.30% (CI: -0.69% to -7.92%; p = 0.021). Intervention group had: fat mass loss at 6 months, 1.86% (1.54%), net difference 1.96% (CI: -3.82% to 0.11%, p = 0.039); Mediterranean diet score improvement at 3 months, 2 points, net difference 1.62 (CI: 0.263 to 2.968; p = 0.020); and calorie consumption decrease at 6 months, 452 cal, net difference -390 (CI: -701.1 to -78.13; p = 0.015).Conclusions: CM can be an effective strategy to promote weight and body fat loss.Trial registration: ClinicalTrials.gov identifier NCT03823469; preregistered on June 30, 2019.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":"1045-1055"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13116008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147635508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of Parents' and Adolescents' Motivation Before Pediatric Weight Management-Data From the STARKIDS Cohort. 儿童体重管理前父母和青少年动机的决定因素——来自STARKIDS队列的数据。

Obesity (Silver Spring, Md.) Pub Date : 2026-05-01 Epub Date: 2026-04-12 DOI: 10.1002/oby.70185

Anne Herschbach, Rebecca Erschens, Florian Junne, Stefan Ehehalt, Johann Jacoby, Peter Martus, Isabelle Mack, Alisa Weiland, Inga Krauß, Constanze Greule, Guido Zurstiege, Annalena Wels, Sophia Helen Adam, Andreas Hoell, Wolfgang Bethge, Monika Ums, Torben Sammet, Maren Reyer, Olaf Schliesing, Stephan Zipfel, Caterina Gawrilow, Katrin Elisabeth Giel, Katrin Ziser

{"title":"Determinants of Parents' and Adolescents' Motivation Before Pediatric Weight Management-Data From the STARKIDS Cohort.","authors":"Anne Herschbach, Rebecca Erschens, Florian Junne, Stefan Ehehalt, Johann Jacoby, Peter Martus, Isabelle Mack, Alisa Weiland, Inga Krauß, Constanze Greule, Guido Zurstiege, Annalena Wels, Sophia Helen Adam, Andreas Hoell, Wolfgang Bethge, Monika Ums, Torben Sammet, Maren Reyer, Olaf Schliesing, Stephan Zipfel, Caterina Gawrilow, Katrin Elisabeth Giel, Katrin Ziser","doi":"10.1002/oby.70185","DOIUrl":"10.1002/oby.70185","url":null,"abstract":"Objective: Pediatric obesity (OB) treatments show small effects and high dropout rates, potentially due to low motivation in participating families. Motivation prior to a weight management program is referred to as \"readiness to change\" (RTC). Understanding RTC is key to improving outcomes. Previous studies observed determinants for RTC, but results are heterogenous and data about adolescents' RTC are lacking.Methods: Baseline data of the STARKIDS trial were used to find determinants of RTC in (a) adolescents (n = 125), (b) their caretakers (n = 185), and (c) caretakers of younger children (n = 325). Potential determinants were sociodemographic variables, weight, general quality of life (QoL), OB-related QoL, self-efficacy, and body image of caretakers and children. Pearson correlations (t-tests and ANOVA) and multiple linear regression analyses were performed.Results: The RTC of adolescents and of both groups of caretakers was determined by adolescents'/children's OB-related QoL. The RTC of caretakers of younger children was also determined by children's BMI-SDSLMS.Conclusions: OB-related QoL plays a major role in determining adolescents' and caretakers' motivation prior to weight management. In all groups, most significant determinants refer to corresponding family members, showing that the mutual influence is large.Trial registration: German Clinical Trials Register (DRKS) DRKS000228 13 (acknowledged primary register of the World Health Organization).","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":"1115-1127"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13116062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DXA-Derived Abdominal Adiposity and Obesity-Related Cancer Risk Among Postmenopausal Women in the Women's Health Initiative. 在妇女健康倡议中，绝经后妇女中dxa衍生的腹部肥胖和肥胖相关的癌症风险。

Obesity (Silver Spring, Md.) Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1002/oby.70168

Robert M Blew, Shelby G Ziller, Andrew O Odegaard, Bette J Caan, Zhao Chen, Denise J Roe, JoAnn E Manson, Thomas E Rohan, Ashley S Felix, Holly R Harris, Juhua Luo, Dorothy S Lane, Jennifer W Bea

{"title":"DXA-Derived Abdominal Adiposity and Obesity-Related Cancer Risk Among Postmenopausal Women in the Women's Health Initiative.","authors":"Robert M Blew, Shelby G Ziller, Andrew O Odegaard, Bette J Caan, Zhao Chen, Denise J Roe, JoAnn E Manson, Thomas E Rohan, Ashley S Felix, Holly R Harris, Juhua Luo, Dorothy S Lane, Jennifer W Bea","doi":"10.1002/oby.70168","DOIUrl":"10.1002/oby.70168","url":null,"abstract":"Objective: Obesity is associated with the risk of several cancers, yet conventional anthropometric measures do not distinguish the contributions of different compartments of abdominal adipose tissue. This study examined the relationship between visceral (VAT) and subcutaneous (SAT) abdominal adiposity and the incidence of 13 obesity-related cancers (ObRCs) in postmenopausal women.Methods: Data from 9950 postmenopausal participants in the Women's Health Initiative (WHI) dual-energy X-ray absorptiometry (DXA) cohort were analyzed. Abdominal VAT and SAT were quantified from DXA scans using validated imaging software. Fine and Gray competing-risks models estimated associations with ObRC incidence over 177,295 person-years of follow-up.Results: Higher abdominal VAT was significantly associated with higher ObRC risk, independently of BMI, waist circumference (WC), and other confounders. Each 100-cm2 increase in VAT corresponded to a 32% higher risk, with a nearly twofold increase for women in the highest VAT quartile. SAT and the VAT/SAT ratio were also significantly associated with risk, though more modestly. Findings were consistent across BMI, WC, age, and race/ethnicity strata and in time-varying models.Conclusions: Visceral adiposity has a strong, independent association with ObRC risk in postmenopausal women. Incorporating imaging-based body composition measures may improve cancer risk stratification and guide targeted prevention strategies.Trial registration: ClinicalTrials.gov identifier: NCT00000611 https://clinicaltrials.gov/study/NCT00000611.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":"997-1009"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147489283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. 纳曲酮-安非他酮在超重/肥胖和抑郁症状患者中的应用：一项汇总分析

Obesity (Silver Spring, Md.) Pub Date : 2026-05-01 Epub Date: 2026-03-31 DOI: 10.1002/oby.70183

Jena Shaw Tronieri, Robert F Kushner, Caroline M Apovian, Angela Fitch, Christopher Still, Thomas A Wadden

{"title":"Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis.","authors":"Jena Shaw Tronieri, Robert F Kushner, Caroline M Apovian, Angela Fitch, Christopher Still, Thomas A Wadden","doi":"10.1002/oby.70183","DOIUrl":"10.1002/oby.70183","url":null,"abstract":"Objective: The present study examined the safety and efficacy of the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) in individuals with overweight/obesity and mild to moderate symptoms of depression.Methods: Data were pooled from four double-blind, placebo-controlled trials. Participants with baseline Inventory of Depressive Symptomatology-Self-Report scores ≥ 14 suggestive of mild or greater depressive symptoms were included (N = 511). Primary outcomes were 56-week percent weight loss and changes in depression, as well as safety data for psychiatric adverse events (PAEs), depressive symptom increases, and suicidal ideation. Multiple imputation was applied, and outcomes were compared in the intention-to-treat population.Results: In participants with symptoms of depression, 56-week weight loss was significantly greater with NB-ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003). Participants experienced clinically meaningful improvements in depression of -7.1 ± 0.4 with NB-ER and -6.7 ± 0.5 with placebo, with no significant differences between the groups. NB-ER and placebo did not differ in safety signals including PAE occurrence (27.5% NB-ER vs. 22.1% placebo), depressive symptom increases (9.5% NB-ER vs. 8.8% placebo), or suicidal ideation (1.8% NB-ER vs. 2.0% placebo).Conclusions: NB-ER appears to be both safe and effective for weight loss when offered to patients with mild to moderate symptoms of depression.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":"1010-1019"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13116053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0